About Myris Therapeutics
Myris Therapeutics is a private company based in Sharpsburg, Pennsylvania, incorporated in 2022 in Delaware. It has reported $2,049,991 raised in two offerings on Form D since April 2022. Its chief executive is Laura Benjamin.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Sep 1, 2026 | Oct 14, 2026 | $500,000of $4.5M target | 4 | $125K | Convertible Promissory NotesRule 506(b) | Form D ↗ |
| Apr 14, 2022 | Apr 29, 2022 | $1,549,991of $2.0M target | 8 | $193K | EquityRule 506(b) | Form D ↗ |
| Total, two offerings | $2,049,991 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Myris Therapeutics's Form D filed Oct 14, 2026.
Earlier filings also listed Patrick Bailey (executive officer, last listed Apr 2022), Jean Pineault (ceo & president, director, last listed Apr 2022) and Autumn Gindlesberger (executive officer, last listed Apr 2022).